semaj83/ctmatch_classification huggingface dataset:
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 60.0-999.0,  COPD Exacerbation Presence of purulent sputum documented by colorimetric assay (Allegra et al., Resp Med 2005), plus at least two of the following signs-symptoms Increased cough Increased dyspnea Increase in sputum volume appeared at least 3 days previous antibiotic treatment with any medication (eg, amoxicillin, amoxicillin / clavulanate, cephalosporins or macrolides) with the exception of quinolones, conducted for at least 3 days with persistence or worsening of symptoms and subsequent use of hospital ≥ 60 years FEV1 <80% and ≥ 30% and ratio FEV 1 / FVC <70% chest x-ray negative for inflammatory infiltrates informed consent  asthma pulmonary neoplasms a history of allergy or hypersensitivity to quinolones impracticability in oral antibiotic and / or altered ability to absorption by the gastrointestinal system a history of epilepsy, seizures, cerebral vascular disease (stroke cerebri within 6 months) history of tendinopathy note or severe renal impairment creatinine> than twice the upper limit of the normal range or hepatic impairment (AST and / or ALT> twice the upper limit of the normal range) patients with sepsis, tuberculosis or other infections in other organs or systems cystic fibrosis patients with inherited tolerance to intolerance, Lapp lactase deficiency or glucose-galactose malabsorption, or deficiency of the enzyme glucose-6-phosphate dehydrogenase
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  COPD i. Patients with a diagnosis of COPD, emphysema, or chronic bronchitis ii. Age ≥ 40 years-old iii. Smoking history ≥ 10 pack-years iv. Presentation to the emergency room with increased dyspnea, increased sputum, or increased cough v. Admission to the hospital  i. Alternative diagnosis for cause of dyspnea, increased sputum or cough ii. Patients who requires intubation at time of recruitment iii. Patients who are unable to give consent iv. Patients who are pregnant or could be pregnant or are currently breast-feeding v. Women of child-bearing age who cannot use methods of contraception as described in the consent, including condoms, female condoms, cervical caps, diaphragms, and intra uterine devices vi. Patients who were previously entered into the trial and are re-admitted to the hospital with a new COPD exacerbation
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Diabetes Chronic Obstructive Pulmonary Disease Diabetic patients with COPD exacerbation  Patients treated with steroids during the previous 3 months
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Bronchiectasis Age ≥ 18 years HRCT-diagnosed Bronchiectasis Capable of providing written informed consent  Patient judged to have poor compliance Cystic fibrosis bronchiectasis
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 17.0-999.0,  Cystic Fibrosis Diagnosis of Cystic Fibrosis based on genetic testing and/or sweat chloride levels Chronic infection with Pseudomonas aeruginosa Patients able to produce daily sputum samples Current history of at least two pulmonary infective exacerbations in the past 12 months Able to give written informed consent  Unable to provide written informed consent Patients unable to produce daily sputum samples Fewer than two infective pulmonary exacerbations in 12 months
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Obstructive Pulmonary Disease (COPD) Adults, either sex, older or equal than 40 years of age For female patients, the following conditions are to be met has been postmenopausal for at least 1 year, or is surgically incapable of bearing children, or is of childbearing potential, and the following conditions are met has a negative pregnancy test (urine or serum-based) immediately before study entry (i.e., before the start of treatment or any other study procedure that could potentially harm the fetus), and one or more of following must agree to abstinence or use an accepted method of contraception. The subject must agree to continue with the same method throughout the study having only female sexual partners sexual relationship with sterile male partners only  Severe exacerbation: defined by need for ventilatory support (indicated by severe dyspnea with failure to respond to emergency treatment and/or persistent hypoxemia (PaO2 <50 mm Hg despite O2 administration and / or respiratory acidosis (pH <7.35 and PaCO2> 45mmHg)) or mental confusion or circulatory insufficiency (need of vasopressors) Fever (>38.5°C) Known impaired hepatic or renal function Active or suspected tuberculosis infection of the respiratory tract Acute exacerbation of asthma Suspected or known hypersensitivity to, or suspected serious adverse reaction to sultamicillin; suspected or known hypersensitivity to penicillins or cephalosporins Immunosuppression or Immunosuppressive therapy (cytostatic chemotherapy within last 28 days or neutropenia (neutrophils < 1000/µ)l; systemic corticosteroids (≥20 mg prednisolon equivalent/day > 14 days; HIV-infection; immunosuppression after organ or bone marrow transplant) Patients with metastatic or hematological malignancy, splenectomized patients or patients with known hyposplenia or asplenia Oral/parenteral antibiotic use within 30 days prior to randomization (a singular administration of antibiotics prior to randomization is allowed)
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Obstructive Lung Disease 3. and Recruitment Doctors in Pulmonary Medicine Department, Bispebjerg Hospital, which is involved directly in the treatment of patients who are potential candidates can be created as "investigator" after proper information and training. Then, these doctors patients. is based on the following in-and  and after oral and written participant information The following must all be met for the patient can be First The patient must have confirmed / suspected COPD, and must be hospitalized with COPD exacerbation Second The patient must be an adult (more than 18 years) and age. 3rd There must be a signed informed consent 4th Patients included only on weekdays Exclusions: The following should NOT be satisfied that the patient can be First The patient can not understand or relate to the oral or written information Second The patient has previously been involved in the study
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 0.0-5.0,  Pneumonia Bronchiolitis Asthma All children below 5 exceeding WHO age-dependent tachypnea criteria
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 40.0-85.0,  Chronic Obstructive Pulmonary Disease Endothelial Dysfunction COPD patients in stable condition ( without exacerbation min 1 months ago) Over 40 years History of at least 10 py  acute exacerbation of COPD active malignancy autoimmune disease acute myocardial infarction diabetes mellitus with late complications congestive heart failure women of childbearing potential
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  COPD Chronic Obstructive Pulmonary Disease Diagnosis of stable COPD years or older Smoking history of at least 10 pack-years Forced Expiratory Volume in one second (FEV1) ≤ 70 % of predicted value and FEV1 / Forced Vital Capacity (FVC) < 0.70 Dyspnea ≥ 2 on the Medical Research Council (MRC) scale At least 2 exacerbations requiring prednisone treatment in the past 3 years Using a written action plan and having demonstrated adequate use of the self-administered antibiotic & prednisone (adequate use defined as prednisone started by the patient within 72 hours of symptom worsening and patient called the case-manager as recommended for following the response) Already on Advair BID (twice a day) as a maintenance therapy or able to switch over to Advair if already taking another combination medication (Symbicort) as maintenance therapy for COPD  History of asthma or allergic rhinitis before the age of 40 Regular use of oxygen, oral corticosteroids, antibiotics Unstable or life threatening co-morbid condition Medical conditions or taking medications known to affect tremor and/or heart rate (HR) Pre-existing medical conditions or on concomitant medications contraindicated with salmeterol or fluticasone propionate (e.g. monoamine oxidase inhibitors and tricyclic antidepressants, beta-adrenergic receptor blocking agents, non potassium-sparing diuretics, inhibitors of cytochrome P450 (ritonavir, ketoconazole)) On theophyllines Colonized with pseudomonas aeruginosa
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 50.0-85.0,  Chronic Obstructive Pulmonary Disease Signature of informed consent COPD patients with age raging from 50 to 85 years old Patients with at least a history of COPD of one year COPD patients clinically stable in the last three months COPD subjects with Forced Expiratory Volume at one second (FEV1)<50% of predicted value COPD subjects with Residual Volume (RV) >125% predicted value FEV1/Forced Vital Capacity (FVC) <88% (males) or <89% (females) of Low Levels of Normality (LLN) COPD former or active smokers with at least a smoking history of 20 pack year  Acute Bronchial Exacerbation at recruitment Fertile women with age between 18 and 50 years old or with active period Pregnancy Subjects enrolled in other clinical trials or that have taken part in one of them in the month preceding the enrollment FEV1/FVC more than 70% of predicted value in basal conditions FEV1 more than 70% of predicted value in basal conditions Known deficit of alpha 1 antitrypsin Subjects that underwent a Lung Volume Reduction Surgery (LVRS) Subjects with known positivity to Human Immunodeficiency Virus (HIV) Misuse of alcool or drugs
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 58.0-72.0,  Chronic Obstructive Pulmonary Disease ex-smokers (> 10 packets-year) with moderate-severe COPD patients
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Obstructive Pulmonary Disease Hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease Age≥ 40years old  The first diagnosis which caused hospitalization is not acute exacerbation of chronic obstructive pulmonary disease Chest radiography shows congestive heart failure Chest CT shows lung cancer, active pulmonary tuberculosis, pulmonary thromboembolism or interstitial lung diseases Serious cardiac failure, renal insufficiency or hepatic dysfunction
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 40.0-75.0,  Chronic Obstructive Pulmonary Disease Post bronchodilator forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio less than 0.7 Stable phase of COPD History of exposure to respirable silica dust, nonsmokers with absence of passive exposure to tobacco smoke or history of exposure to polycyclic aromatic hydrocarbons exhaust, nonsmokers with absence of passive exposure to tobacco smoke or current tobacco smokers without history of occupational exposure COPD risk factor exposure (occupational or tobacco smoke) duration not less than 12 months Male Caucasian Age of 40 years old Control group  history of biomass smoke exposure age less than 40 and above 75 years old current COPD exacerbation concomitant asthma tuberculosis and other pulmonary diseases allergic and autoimmune disorders active infections immunodeficiency, including HIV infection parasitological diseases malignancies
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  COPD Exacerbation clinical and spirometric diagnosis of COPD for study group: clinical symptoms of exacerbation and infection of low airway Signed informed consent  No acceptance of informed consent The STUDY GROUP: treatment with antibiotic more tan 2 days before consultation Another entity known pulmonology other than COPD (non-obstructive disorders, bronchiectasis, interstitial lung disease patients, severe pulmonary hypertension, hypoventilation) Chronic treatment with oral corticosteroids or immunosuppressive drug severe organ comorbidity such as cancer in advanced or terminal phase, pulmonary tuberculosis with important involvement, severe pneumoconiosis Severe alteration of nutritional status Heart disease evolved Limitation for understanding the study (including psychiatric disorder, language problem, social or cultural differences, etc.)
Patient description: A 63-year-old man presents with cough and shortness of breath. His past medical history is notable for heavy smoking, spinal stenosis, diabetes, hypothyroidism and mild psoriasis. He also has a family history of early onset dementia. His symptoms began about a week prior to his admission, with productive cough, purulent sputum and difficulty breathing, requiring him to use his home oxygen for the past 24 hours. He denies fever. On examination he is cyanotic, tachypneic, with a barrel shaped chest and diffuse rales over his lungs. A chest x-ray is notable for hyperinflation with no consolidation.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Community Acquired Pneumonia Adults aged 18 to 85, inclusive Has given written, informed consent Has acute illness with onset within previous 7 days Has at least 2 of the following symptoms Difficulty breathing or shortness of breath Cough Production of purulent sputum Pleuritic chest pain Has at least 2 vital sign abnormalities Fever (> 38°C or < 35°C)  Contra-indication to the administration of any of the study treatments, such as hypersensitivity to any of the glycopeptide agents, beta-lactam agents, linezolid or macrolide antibiotics, or current or recent (within 2 weeks) use of MAO inhibitors or serotonergic antidepressants (within 5 weeks for fluoxetine) (see Section 5.5.1) Has received antibiotic therapy in the 4 days prior to screening, with the following exception: up to 25% of patients may have received a single dose of a short acting (half life < 8 hours) antibiotic Has aspiration pneumonia Has hospital acquired or ventilator associated pneumonia, or healthcare associated pneumonia, or 2 or more days in hospital in the previous 90 days Has cystic fibrosis or known or suspected Pneumocystis pneumonia or known or suspected active tuberculosis Females of child-bearing potential who are unable to take adequate contraceptive precautions, have a positive pregnancy result within 24 hours prior to study entry, are known to be pregnant, or are currently breastfeeding an infant Has primary or metastatic lung cancer Has known bronchial obstruction or a history of post-obstructive pneumonia Requires admission to ICU at baseline Has empyema requiring drainage